LB PHARMACEUTICALS INC 8-K

What Happened

• On Feb 5, 2026 (filing), LB Pharmaceuticals announced a private placement agreement entered Feb 4, 2026 to raise approximately $100.0 million in gross proceeds by issuing 3,306,571 shares of common stock and pre‑funded warrants to purchase up to 1,417,107 additional shares. The offering price was $21.17 per share and $21.1699 per pre‑funded warrant. The offering is expected to close on or about Feb 6, 2026. Placement agents are Leerink Partners, Piper Sandler and Stifel.
• The company also filed a Registration Rights Agreement to register the resale of the Shares and Warrant Shares (Form S‑1 to be filed within 60 days of closing and declared effective as soon as possible, no later than 90 days after filing).

Key Details

• Securities: 3,306,571 common shares; pre‑funded warrants to acquire up to 1,417,107 shares.
• Pricing: $21.17 per share; $21.1699 per pre‑funded warrant (exercise price $0.0001). Pre‑funded warrants are exercisable immediately, do not expire, and include ownership caps (generally 4.99% or 9.99%, adjustable up to 19.99% with notice).
• Use of proceeds: fund a planned Phase 2 trial of LB‑102 as an adjunctive treatment for major depressive disorder (MDD), plus working capital and general corporate purposes.
• Clinical plan/timeline: Phase 2 to initiate in early 2027, ~380 patients at ~50 U.S. and European sites, randomized 1:1 LB‑102 vs placebo (15 mg and 25 mg once daily), six‑week primary endpoint (MADRS‑10 at week six); topline results expected in H1 2029.

Why It Matters

• The financing should provide near‑term capital specifically to support the planned Phase 2 trial of LB‑102, reducing near‑term funding uncertainty tied to that program.
• Investors should note dilution implications: new shares plus potential Warrant Shares will increase outstanding share count; pre‑funded warrants are immediately exercisable (subject to ownership caps), which can shorten the timeline for when those shares might enter the float.
• The Phase 2 design and projected timeline give investors a clear milestone (trial start in early 2027; topline in H1 2029) to monitor LB‑102’s development progress and potential value inflection points.